Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful
immunotherapeutic tools for combating hematological diseases confronted with pressing …

The immune system evolved to distinguish non-self from self to protect the organism. As
cancer is derived from our own cells, immune responses to dysregulated cell growth present …

The prognosis for patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-
NHL) remains poor, with a need for alternatives to current salvage therapies. Loncastuximab …

Relapsed and refractory acute lymphoblastic leukemia (ALL) remains difficult to treat, with
minimal improvement in outcomes seen in more than 2 decades despite advances in upfront …

Simple Summary HER2-positive breast cancer (BC), which accounts for~ 20% of BC, is one
of the more aggressive and has the worst overall survival rate among them. These patients …

Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cell has changed
the treatment landscape of B-cell non-Hodgkin's lymphoma (NHL), especially for aggressive …

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to
provide guidance on the management of immune-related adverse events resulting from …

We report the findings from the first 10 patients with chemotherapy-refractory chronic
lymphocytic leukemia (CLL) or relapsed B-cell acute lymphoblastic leukemia (ALL) we have …

Bispecific antibodies (bsAb) that target two independent epitopes or antigens have been
extensively explored in translational and clinical studies since they were first developed in …

Acute myeloid leukemia (AML) is a malignant disorder derived from neoplastic myeloid
progenitor cells characterized by abnormal proliferation and differentiation. Although novel …